Multi-Center Study Evidences Greater AE Risks with PK13 Inhibitor use in B-Cell Malignancy-based Clinical Trials Sample

Multi-Center Study Evidences Greater AE Risks with PK13 Inhibitor use in B-Cell Malignancy-based Clinical Trials Sample

A multi-center research team from universities and health systems revealed that treatment with phosphatidylinositol 3-kinase inhibitors improves survival for patients with B cell malignancies however also increases incidents of adverse events including pneumonitis,...
FDA Halting Fecal Matter Transplant Studies to Ensure Proper Procedures in Place Post Serious Adverse Event including a Death

FDA Halting Fecal Matter Transplant Studies to Ensure Proper Procedures in Place Post Serious Adverse Event including a Death

The U.S. Food and Drug Administration (FDA) has issued a safety alert for fecal transplant procedures after two immune-compromised patients contracted drug-resistant infections. The patients received transplants from the same donor, and one of the patients died....

Pin It on Pinterest